Dr. Reddy’s Laboratories Ltd. announced the launch of Valsartan Tablets, USP, a therapeutic equivalent generic version of Diovan® (valsartan) Tablets approved by the U.S. Food and Drug Administration (USFDA).
The Diovan® brand and generic market had U.S. sales of approximately $150 million MAT for the most recent twelve months ending in October 2021 according to IQVIA Health*.
Dr. Reddy’s Valsartan Tablets, USP are available in 40 mg in bottle count size of 30, and 80 mg, 160 mg and 320 mg tablets in bottle count sizes of 90.
About Dr Reddy’s
Ask any of the 20,000 employees at Dr. Reddy’s why they come to work every day, and you are bound to hear, because ‘Good Health Can’t Wait.’ These simple words describe the deep-rooted belief that drives us. Sometimes, the simplest words describe the most profound truths.
'Good Health’ is always our goal. We see medicines not just as molecules, but as means to help patients regain their health. As a leader in the pharmaceutical industry, we realize our unique role; we have the ethical and moral imperative to ensure good health can be delivered to those who need it, and to promote wellness among them.
'Can't Wait’ reflects our commitment to act with speed to find innovative solutions that address the unmet needs of patients, and to accelerate access to much-needed medicines for people around the world.
Our belief is guided by our principles - Empathy and Dynamism - which provide both guidance for our current behaviour and inspiration for our future actions.
Stay up to date with the latest news, articles, and events. Plus, get special offers from Tablets & Capsules – all delivered right to your inbox!
Sign up now!